Calliditas Therapeutics AB (NAS:CALT)
$ 21.9 -0.1 (-0.45%) Market Cap: 587.80 Mil Enterprise Value: 582.30 Mil PE Ratio: 0 PB Ratio: 18.56 GF Score: 49/100

Calliditas Therapeutics AB Fireside Chat with Everest Medicines Ltd Transcript

Dec 14, 2022 / 01:00PM GMT
Release Date Price: $19.49 (+1.78%)
Operator

Good morning, and welcome to the Calliditas Therapeutics Fireside Chat. (Operator Instructions) As a reminder, this call is being recorded, and a replay will be made available on the Calliditas website following the conclusion of the event.

I'd now like to turn the call over to Renee Lucander, Chief Executive Officer of Calliditas Therapeutics. Please go ahead, Renee.

Renee Aguiar;Lucander;publ;CEO
Calliditas Therapeutics AB

()-

Thank you very much, and welcome, everybody, to this fireside chat. So with me today I have some of our -- from our partner Everest Medicines. So the people joining us here on the call is Rogers Luo who's CEO of Everest Medicines; we have Dr. Zhengying Zhu who is CMO; and we have Ian Woo who is President and CFO of Everest Medicines. The Q&A is going to be managed by Ashley Robinson from LifeSci when we get to that section.

So first of all, I just want to give you a very brief, because I know you haven't come to this to listen to me talk about Calliditas, but I'm

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot